Comparison of anti-Müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis.


Journal

Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849

Informations de publication

Date de publication:
27 Jun 2023
Historique:
received: 08 02 2023
accepted: 07 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 27 6 2023
Statut: epublish

Résumé

Increasingly studies reported that the Anti-Müllerian hormone (AMH) seems to be a promising and reliable marker of functional ovarian follicle reserve, even better than the AFC test. Our study aimed to conduct a meta-analysis to assess the predictive value of AMH and AFC for predicting poor or high response in IVF treatment. An electronic search was conducted, and the following databases were used: PubMed, EMBASE, and the Cochrane Library (up to 7 May 2022). The bivariate regression model was used to calculate the pooled sensitivity, specificity, and area under the receiver operator characteristic (ROC) curve. Subgroup analyses and meta-regression also were used in the presented study. Overall performance was assessed by estimating pooled ROC curves between AMH and AFC. Forty-two studies were eligible for this meta-analysis. Comparison of the summary estimates for the prediction of poor or high response showed significant difference in performance for AMH compared with AFC [poor (sensitivity: 0.80 vs 0.74, P < 0.050; specificity: 0.81 vs 0.85, P < 0.001); high (sensitivity: 0.81 vs 0.87, P < 0.001)]. However, there were no significant differences between the ROC curves of AMH and AFC for predicting high (P = 0.835) or poor response (P = 0.567). The cut-off value was a significant source of heterogeneity in the present study. The present meta-analysis demonstrated that both AMH and AFC have a good predictive ability to the prediction of poor or high responses in IVF treatment.

Sections du résumé

BACKGROUND BACKGROUND
Increasingly studies reported that the Anti-Müllerian hormone (AMH) seems to be a promising and reliable marker of functional ovarian follicle reserve, even better than the AFC test. Our study aimed to conduct a meta-analysis to assess the predictive value of AMH and AFC for predicting poor or high response in IVF treatment. An electronic search was conducted, and the following databases were used: PubMed, EMBASE, and the Cochrane Library (up to 7 May 2022). The bivariate regression model was used to calculate the pooled sensitivity, specificity, and area under the receiver operator characteristic (ROC) curve. Subgroup analyses and meta-regression also were used in the presented study. Overall performance was assessed by estimating pooled ROC curves between AMH and AFC.
RESULTS RESULTS
Forty-two studies were eligible for this meta-analysis. Comparison of the summary estimates for the prediction of poor or high response showed significant difference in performance for AMH compared with AFC [poor (sensitivity: 0.80 vs 0.74, P < 0.050; specificity: 0.81 vs 0.85, P < 0.001); high (sensitivity: 0.81 vs 0.87, P < 0.001)]. However, there were no significant differences between the ROC curves of AMH and AFC for predicting high (P = 0.835) or poor response (P = 0.567). The cut-off value was a significant source of heterogeneity in the present study.
CONCLUSIONS CONCLUSIONS
The present meta-analysis demonstrated that both AMH and AFC have a good predictive ability to the prediction of poor or high responses in IVF treatment.

Identifiants

pubmed: 37370145
doi: 10.1186/s13048-023-01202-5
pii: 10.1186/s13048-023-01202-5
pmc: PMC10294345
doi:

Substances chimiques

Anti-Mullerian Hormone 80497-65-0
Follicle Stimulating Hormone 9002-68-0

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117

Subventions

Organisme : the Yunnan Ten Thousand Youth Talent Program
ID : [2018]73
Organisme : the Medical Discipline Leader in Health Commission of Yunnan Province
ID : D-2019004

Informations de copyright

© 2023. The Author(s).

Références

Fertil Steril. 2013 Aug;100(2):430-7
pubmed: 23668992
Hum Reprod. 2008 Jan;23(1):160-7
pubmed: 18000172
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
J Assist Reprod Genet. 2012 Feb;29(2):117-25
pubmed: 22086616
Clin Lab. 2014;60(10):1717-23
pubmed: 25651719
J Assist Reprod Genet. 2013 Jun;30(5):657-65
pubmed: 23508679
Reprod Biomed Online. 2007 Apr;14(4):450-4
pubmed: 17425826
Hum Reprod. 2005 Nov;20(11):3178-83
pubmed: 16113044
Hum Reprod. 2007 Jul;22(7):1932-41
pubmed: 17493981
Hum Reprod. 2008 Jun;23(6):1359-65
pubmed: 18387961
Hum Reprod. 2005 Apr;20(4):915-22
pubmed: 15665015
Hum Reprod Update. 2014 Jan-Feb;20(1):124-40
pubmed: 24077980
Fertil Steril. 2006 Mar;85(3):592-6
pubmed: 16500324
Hum Reprod. 2007 Mar;22(3):778-85
pubmed: 17114197
Obstet Gynecol. 2003 Oct;102(4):816-22
pubmed: 14551013
Reprod Biomed Online. 2020 Jul;41(1):29-36
pubmed: 32466992
Gynecol Endocrinol. 2013 Aug;29(8):754-7
pubmed: 23758138
J Obstet Gynaecol. 2017 Jan;37(1):82-88
pubmed: 27976974
Reprod Biol Endocrinol. 2011 Aug 15;9:115
pubmed: 21843363
J Assist Reprod Genet. 2011 Dec;28(12):1197-203
pubmed: 21882017
Gynecol Endocrinol. 2007 Apr;23(4):206-12
pubmed: 17505940
Hum Reprod Update. 2014 May-Jun;20(3):370-85
pubmed: 24430863
J Assist Reprod Genet. 2009 Jun;26(6):319-25
pubmed: 19543966
Hum Reprod. 2007 Jul;22(7):1837-40
pubmed: 17485437
Fertil Steril. 2004 Jan;81(1):35-41
pubmed: 14711542
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Assist Reprod Genet. 2020 Jan;37(1):89-100
pubmed: 31755000
J Ultrason. 2021 Aug 16;21(86):e200-e205
pubmed: 34540273
Reprod Biomed Online. 2015 Oct;31(4):486-96
pubmed: 26283017
Reprod Biol Endocrinol. 2015 Jun 10;13:58
pubmed: 26059906
J Endocrinol Invest. 2015 Sep;38(9):1007-15
pubmed: 25981081
J Assist Reprod Genet. 2001 Mar;18(3):151-5
pubmed: 11411430
Aust N Z J Obstet Gynaecol. 2005 Feb;45(1):20-4
pubmed: 15730360
J Hum Reprod Sci. 2017 Apr-Jun;10(2):91-94
pubmed: 28904496
Fertil Steril. 2018 Aug;110(3):506-513.e3
pubmed: 29960708
Hum Reprod. 2018 Sep 1;33(9):1696-1704
pubmed: 30016431
Fertil Steril. 2002 Feb;77(2):328-36
pubmed: 11821092
Mol Hum Reprod. 2004 Feb;10(2):77-83
pubmed: 14742691
BJOG. 2004 Nov;111(11):1248-53
pubmed: 15521870
Reprod Biomed Online. 2016 Oct;33(4):506-512
pubmed: 27502068
Hum Reprod. 2003 Jan;18(1):35-44
pubmed: 12525438
Hum Reprod. 2008 Sep;23(9):2050-5
pubmed: 18544578
Fertil Steril. 2010 Feb;93(3):855-64
pubmed: 19046583
Hum Reprod. 2002 Dec;17(12):3065-71
pubmed: 12456604
Hum Reprod. 2007 Mar;22(3):766-71
pubmed: 17071823
Arch Gynecol Obstet. 2011 Jun;283(6):1415-21
pubmed: 21562964
Fertil Steril. 2009 Mar;91(3):705-14
pubmed: 18321493
Fertil Steril. 2021 Aug;116(2):575-582
pubmed: 33812650
Fertil Steril. 2003 Aug;80(2):350-5
pubmed: 12909498
Comput Math Methods Med. 2021 Oct 16;2021:7822119
pubmed: 34697556
J Obstet Gynaecol India. 2013 Aug;63(4):268-72
pubmed: 24431654
Hum Fertil (Camb). 2011 Dec;14(4):246-53
pubmed: 22088130
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Feb;33(2):216-20
pubmed: 23443775
Front Endocrinol (Lausanne). 2019 May 28;10:325
pubmed: 31191453
Fertil Steril. 2009 Nov;92(5):1586-93
pubmed: 18930213
Hum Reprod. 2007 Sep;22(9):2414-21
pubmed: 17636277
Hum Reprod Update. 2014 Sep-Oct;20(5):688-701
pubmed: 24821925
Hum Reprod Update. 2011 Jan-Feb;17(1):46-54
pubmed: 20667894
Int J Fertil Steril. 2021 Apr;15(2):115-122
pubmed: 33687164

Auteurs

Yang Liu (Y)

Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China. 13518735544@163.com.

Zhengmei Pan (Z)

Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China.

Yanzhi Wu (Y)

Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China.

Jiamei Song (J)

Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China.

Jingsi Chen (J)

Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China. 86923067@qq.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH